#USA #New York #PreciseBreast #PreciseDx #OncoIntelligence

PreciseDx's Innovative Leap in Breast Cancer Diagnostics

Introduction
PreciseDx, a frontrunner in innovating cancer diagnostics, has made headlines recently with its strategic moves leading up to the launch of its flagship product, PreciseBreast. This novel diagnostic tool, which employs the proprietary OncoIntelligence™ platform, aims to revolutionize the way breast cancer is diagnosed and treated. With an impressive funding increase and key leadership appointments, PreciseDx is setting the stage for significant advancements in oncological care.

Funding Success
On June 18, 2025, PreciseDx announced the successful closure of an $11 million funding round, bringing its total funding to over $43 million. The investment round was spearheaded by renowned entities including Eventide Asset Management, Merck Global Health Innovation Fund, and Philips Ventures, supported by existing investors such as Labcorp and Quest Diagnostics. This financial boost is intended to enhance clinical data collection and facilitate commercial expansion, laying the groundwork for the anticipated 2026 launch of PreciseBreast.

Leadership Changes
To navigate this exciting phase, PreciseDx has appointed Eric Converse as CEO, who brings rich experience from the imaging diagnostics and AI/ML sectors. Joining him is Ed Sitar, newly appointed CFO, whose robust background spans over three decades in financial leadership within diagnostics. Together, they aim to steer PreciseDx towards its mission of delivering precision-driven breast cancer management solutions.

The Vision of PreciseBreast
PreciseBreast is more than just a diagnostic tool; it is a breakthrough that promises to enhance the decision-making process for both oncologists and patients. Harnessing the power of AI, the test integrates seven morphologic features with four clinical parameters to yield an OncoIntelligence Score ranging from 0 to 100. This score provides crucial insights into a patient’s risk of recurrence, paving the way for tailored treatment plans.

The test's efficacy has been validated through rigorous studies involving over 3,000 breast cancer cases, confirming its reliability in stratifying patients based on disease recurrence risk over six years. In the words of Carlos Cordon-Cardo, MD, PhD, the Founder of PreciseDx, "This is a defining moment for PreciseDx and our endeavor to empower both physicians and patients with biologically-informed choices in breast cancer management." He emphasizes how PreciseBreast represents the inception of a new era in diagnostic precision.

Broader Implications for Cancer Care
The successful rollout of PreciseBreast not only has the potential to change the landscape of breast cancer diagnostics but also opens avenues for guiding treatment decisions in various solid tumors. CEO Eric Converse noted, "With the initial success of PreciseBreast, we can extend the capabilities of OncoIntelligence to improve patient outcomes across other types of cancer." This speaks volumes about the company's commitment to leveraging technology in the fight against cancer.

Conclusion
As PreciseDx gears up for its major product launch in 2026, the dedication of its leadership team and the confidence of its investors signal a promising future for breast cancer diagnostics. With the innovative approach that PreciseBreast embodies, the company aims to transform patient care and provide hope to countless individuals and families impacted by breast cancer. For further insights on their groundbreaking work, visit precisedx.ai.

Contact Information
For more inquiries, please reach out via email to press@precisedx.ai.

Note: Mount Sinai and Carlos Cordon-Cardo have a financial interest in PreciseDx, and their statements could yield financial benefits.